Hyderabad-based pharma player Laurus Labs has received a licence from the Defence Research & Development Organisation (DRDO) for manufacturing and marketing Covid-19 drug 2-Deoxy-D-Glucose (2-DG) in India. The licence to Laurus Labs has been granted by DRDO as part of efforts to make the drug affordable and accessible to patients.
DRDO had recently invited expression of interest (EoI) from other pharma companies for manufacturing this drug and had said it would grant licences to 15 companies on a first-come, first-served basis. Meanwhile, the Council of Scientific & Industrial Research institution Indian Institute of Chemical Technology (CSIR-IICT) has been licencing the know-how for 2-DG synthesis to other companies, including Lee Pharma, Suven Pharma, Anthem Biosciences and Nosch Labs.
Exams such as SSC, Banking, Railways, and state-level tests offer paths to prestigious positions in…
Mysore, a city in the southern state of Karnataka, India, is famous for its rich…
The upcoming Champions Trophy 2025 marks the ninth edition of the ICC Champions Trophy, featuring…
The 2025 ICC Champions Trophy is set to mark the ninth edition of this prestigious…
India's nuclear program focuses on using nuclear energy for peaceful purposes, like producing electricity and…
Uttar Pradesh, located in northern India, is the country's most populous state. Known for its…